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Context: Pituitary stalk interruption syndrome (PSIS, ORPHA95496) is a congenital defect of the
pituitary gland characterized by the triad of a very thin/interrupted pituitary stalk, an ectopic (or
absent) posterior pituitary gland, and hypoplasia or aplasia of the anterior pituitary gland. Complex
genetic patterns of inheritance of this disorder are increasingly recognized.
Objective: The objective of this study was to identify a genetic cause of PSIS in an affected child.
Methods: Whole exome sequencing (WES) was performed by using standard techniques, with
prioritized genetic variants confirmed via Sanger sequencing. To investigate the effects of one
candidate variant on mutant WDR11 function, Western blotting and coimmunofluorescence were
used to assess binding capacity, and leptomycin B exposure along with immunofluorescence was
used to assess nuclear localization.
Results:Wedescribe a childwhopresented in infancywith combined pituitary hormone deficiencies
and whose brain imaging demonstrated a small anterior pituitary, ectopic posterior pituitary, and a
thin, interrupted stalk. WES demonstrated heterozygous missense mutations in two genes required
for pituitary development, a known loss-of-function mutation in PROKR2 (c.253C.T;p.R85C)
inherited from an unaffected mother, and a WDR11 (c.1306A.G;p.I436V) mutation inherited
from an unaffected father. Mutant WDR11 loses its capacity to bind to its functional partner,
EMX1, and to localize to the nucleus.
Conclusions: WES in a child with PSIS and his unaffected family implicates a digenic mechanism of
inheritance. In cases of hypopituitarism in which there is incomplete segregation of a monogenic
genotype with the phenotype, the possibility that a second genetic locus is involved should be
considered. (J Clin Endocrinol Metab 102: 2501–2507, 2017)
Pituitary stalk interruptionsyndrome (PSIS,ORPHA95496)is a congenital defect of the pituitary gland that is
characterized by the triad of a very thin or interrupted
pituitary stalk, an ectopic or absent posterior pituitary
gland, and hypoplasia or aplasia of the anterior pituitary
gland. Patients with PSIS may present with heterogeneous
clinical features resulting from isolated or combined
hypothalamic-pituitary hormone deficiencies. The rare
occurrence of families in which several members have PSIS
has suggested that at least in some cases PSISmaybe genetic
(1, 2), andmutations in genes encoding proteins involved in
the Wnt, Notch, and Shh signaling pathways that are
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critical for hypothalamic–pituitary development have been
reported in some patients with PSIS (3). Nevertheless, in
most cases the cause of PSIS remains unknown. We
present a case of PSIS with multiple anterior pituitary
deficiencies in which whole exome sequencing (WES)
analysis identified two heterozygous mutations, thereby




Samples were collected under an approved institutional re-
view board protocol of the Children’s Hospital of Philadelphia;
the corresponding study was conducted according to the
Declaration of Helsinki. Written, informed consent or assent, as
appropriate, was obtained from all participants before their
inclusion.
Case presentation
Relevant clinical details were abstracted from the electronic
medical record.
Biochemical and genetic analyses
We extracted DNA from peripheral bloodmononuclear cells
from the proband and his unaffected parents, performed exome
capture and sequencing, and read processing, mapping to hu-
man genome reference (GRCh37-derived alignment set used in
1000 Genomes Project), variant calling, annotations, and fil-
tering for rare variants affecting the coding sequence and/or
consensus splice sites, as previously described (4). The family
pedigree (Fig. 1) did not suggest a specific mode of inheritance,
so we considered nonsynonymous, splice-altering variants, and
frameshift variants cosegregating with the disease under de
novo dominant or recessive inheritance model in the family
with a minor allele frequency ,1% in public databases (i.e.,
1000 Genomes Project and National Heart, Lung, and Blood
Institute ESP6500SI). Subsequent gene prioritization was on the
basis of deleterious prediction, biological, and clinical relevance,
as suggested by existing databases (i.e., Online Mendelian In-
heritance in Man and Human Gene Mutation Database).
However, because we failed to identify any candidates relevant
to the phenotype under either the dominant or the recessive
model, we next focused on a possible digenic mode of in-
heritance by identifying variants in the proband that were
shared with either parent. We validated mutation candidates by
Sanger sequencing and used in silico tools (5, 6) to predict their
effects. Deletion/duplication testing was also performed in
PROKR2 by using standard techniques (Fulgent Diagnostics,
Temple, CA). Salivary DNA was collected from the unaffected
sister to assess her status for the identified variants. All bio-
chemical analyses were performed in commercial reference
laboratories using standard techniques.
Mutagenesis
The full-length WDR11 complementary DNA in pcDNA–
green fluorescent protein (GFP) or pcDEST-Myc vector was
mutagenized by using a Q5 site-directed mutagenesis kit (New
England BioLabs, Ipswich, MA) to introduce the c.1306A.G
variant, following the manufacturer’s protocol. Briefly, the nu-
cleotide exchange was introduced by using Q5 Hot Start High-
Fidelity DNA Polymerase with “nonoverlapping” mutagenic
primers (NEBase Changer; New England BioLabs) via poly-
merase chain reaction run for 25 cycles of 98°C for 30 seconds,
98°C for 10 seconds, 60°C for 30 seconds, 72°C for 5 minutes,
and 72°C for 2 minutes. The products were ligated at room
temperature for 5 minutes and transformed into Top10 chemi-
cally competent cells [One Shot Top10 chemically competent
Escherichia coli (Thermo Fisher Scientific, Hertfordshire, United
Kingdom)]. Mutated plasmid constructs were verified by se-
quencing (Source Bioscience, Nottingham, United Kingdom).
Sequences of primers used are available upon request.
Coimmunoprecipitation and Western blot analysis
HEK293T cells cultured in Dulbecco’s modified Eagle
medium supplemented with 2 mM L-glutamine, 100 mg/mL
penicillin/streptomycin, and 10% fetal bovine serum
(Sigma-Aldrich, St. Louis, MO) were transfected with plasmid
constructs expressing Myc-tagged WDR11 or hemagglutinin-
tagged EMX1 using Fugene (Promega, Madison, WI). At
48 hours after transfection, total cell lysates were extracted
with the lysis buffer (50 mM HEPES, 150 mM NaCl, 10%
glycerol, 1% Nonidet P-40, and 1 mM EDTA) containing
protease inhibitor cocktail (Sigma-Aldrich) and phosphatase
inhibitor (Sigma-Aldrich). After incubation on ice for 10 minutes
and centrifugation for 10 minutes at 4°C, the precleared lysate
(500 mg – 1 mg protein) was incubated with anti-Myc antibody
(M4439, Sigma-Aldrich) and protein A/G-Agarose beads (Santa
Cruz Biotechnology, Dallas, TX) overnight at 4°C on a rotating
wheel. The immune complexes on the beads were washed four
times with the lysis buffer, separated by sodium dodecyl sulfate–
polyacrylamidegel electrophoresis and transferred toHybond-ECL
membrane (Amersham, GE Life Sciences, Marlborough, MA),
which was probed with anti-WDR11 (1:500, ab175256, Abcam)
and anti-EMX1 (1:500, PA5-35373; Invitrogen, Carlsbad, CA)
antibody diluted in blocking buffer (5% skimmilk in Tris-buffered
saline with 0.05% Tween 20).
Immunofluorescence
GFP-tagged wild-type (WT) andmutantWDR11 expression
constructs were transfected intoHEK293T. After 48 hours, cells
were treated with leptomycin B (10 ng/mL) for 10 hours before
being fixed with 4% paraformaldehyde. After being washed
three times in phosphate-buffered saline, the nuclei were
counterstained with 40,6-diamidino-2-phenylindole (DAPI) and
the cover slips were mounted in Mowiol 4-88 (Fluka; Sigma-
Aldrich). Images were analyzed by using Zeiss Axioplan 2
Upright fluorescence microscope (Carl Zeiss, Oberkochen,
Germany) and ImageJ software (National Institutes of
Health, Bethesda,MD). In each experiment, approximately 200
cells were scored for the nuclear or cytoplasmic location of
WDR11 based on the GFP signal at 488 nm, against the total
cells in the field based on the DAPI signal at 405 nm.
Results
The proband was the 2.92-kg product of a 39-week ges-
tation, born to a 45-year-old gravida 2, para 1, abortion 0,
mother (Fig. 1). He is of Ashkenazi Jewish heritage andwas
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conceived by in vitro fertilization and underwent targeted
preimplantation genetic diagnosis because both parents are
carriers for Gaucher disease and familial hyperinsulinism.
He is a carrier of GBA (MIM 606463; GenBank:
NM_001005741.2; rs7673715) c.1226A.G; p.N409S and
ABCC8 (MIM 600509; NM_000352.4; rs151344623)
c.3989-9G.A mutations.
He developed transient, mild hypoglycemia within the
first 36 hours of life and was diagnosed with central
congenital hypothyroidism on the basis of low thyroid
hormone levels on newborn screening. Magnetic reso-
nance imaging of the brain showed small anterior pitu-
itary and ectopic posterior pituitary with a thin and
interrupted pituitary stalk, consistent with PSIS. Hy-
drocortisone replacement was begun at 6 weeks of life
based on low serum cortisol levels of ;1 to 2 mg/dL. At
birth he was thought to have a normal-sized phallus, but
at 8 months of life he received testosterone, 25 mg in-
tramuscularly every 3 weeks 3 6, for small phallus.
Growth hormone status was initially normal, and his
length was in the 25th to 50th percentile until age ;16
to 18months, afterwhich hemade little gain in length, such
that by age 2 8/12 years, his height was below the first
percentile. His head circumference demonstrated a similar
pattern. His weight increased to within the 50th to 75th
percentile by around age 12 months but also faltered
thereafter. He begun receiving recombinant human growth
hormone (GH) at age 2 9/12 years because of lack of
statural growth (height standard deviation, 21.8), a very
low random growth hormone level of 0.93 ng/mL, low
insulin-like growth factor-1 level of 27 ng/mL, and a low
insulin-like growth factor-bindingprotein3 level of 0.6mg/L,
Figure 1. Pedigree and sequencing chromatograms. (a) Pedigree: The affected proband is indicated with an arrow (gray square). The genotypes
are indicated for each individual. (b) A sequence chromatogram showing the PROKR2 (c.253C.T;p.R85C) mutation. (c) A sequence chromatogram
showing the WDR11 (c.1306A.G;p.I436V) mutation. In the chromatograms, mutations are indicated with arrows.
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all of which in this clinical context were consistent with GH
deficiency. Both height and weight responded well to GH;
height increased to the 38th percentile andweight to the 20th
percentile after ;15 months of therapy. Neurocognitive
development has been normal.
WES revealed heterozygous mutations in two genes
known to affect hypothalamic and pituitary develop-
ment: c.253C.T;p.R85C in PROKR2 (MIM 607123;
NM_144773.2; rs141090506) inherited from an un-
affected mother and c.1306A.G;p.I436V in WDR11
(MIM 606417; NM_018117.11; rs34602786) inherited
from an unaffected father, both confirmed by Sanger
sequencing (Fig. 1). Additional candidates were consid-
ered under de novo, X-linked, and recessive models and
were excluded because of a lack of pathogenicity or
relevance to the phenotype (Supplemental Table 1). A
clinically unaffected sister carried only the PROKR2
missense mutation (Fig. 1). Publicly available databases
show that PROKR2 missense mutation is present in
the population with a minor allele frequency (MAF)
of 0.0005024 in the ExAC database (http://exac.
broadinstitute.org/gene/ENSG00000101292) and is ab-
sent in the 1000 Genomes Project and in 6503 exomes
from the Exome Sequencing Project (ESP6500SI).
Wewere unable to identify a point mutation, deletion, or
duplication in the second PROKR2 allele, and therefore the
WDR11p.I436Vvariant became relevant on the basis of the
involvement of WDR11 mutations in other pituitary dis-
orders. This variant is rare, and publicly available databases
show it has a MAF of 0.001307 in the ESP6500SI (http://
evs.gs.washington.edu/EVS/) and a MAF of 0.00090840
in the ExAC database (http://exac.broadinstitute.org/gene/
ENSG00000120008). Although in silico prediction tools do
not indicate a high likelihood of pathogenicity (PolyPhen-2
score of 0.000; PROVEAN score of 20.118, neutral), its
location in the functionally significant sixthWDdomain, an
important site for protein–protein interactions, suggested it
could be pathogenic.
To confirm this, we examined the behavior of this rare
variant of WDR11 in two different functional assays in
vitro. WDR11 binds and colocalizes with the EMX1
transcription factor in the nucleus, and this interaction
must be important for its normal function because this
capacity is lost by some, although not all, WDR11
mutations in patients with idiopathic hypogonadotropic
hypogonadism and Kallmann syndrome (7). Our coim-
munoprecipitation Western blot assay indicated that the
p.I436V variant ofWDR11 was unable to bind to EMX1
(Fig. 2). We also evaluated the p.I436V variant in a
second functional assay that is based on the observation
that WT WDR11 can shuttle between nucleus and cy-
toplasm, and treatment with a nuclear export inhibitor,
leptomycin B, induces its accumulation in the nucleus (7).
When we introduced GFP-WDR11 into HEK293T cells,
both the WT and variant WDR11 proteins showed
mainly cytoplasmic location, but when the cells were
treated with leptomycin B, the WT but not the p.I436V
variant showed nuclear localization (Fig. 3). Taken to-
gether, these studies demonstrate that the p.I436V sub-
stitution disrupts the normal function of WDR11 and
provides strong evidence that this is a pathogenic variant.
Discussion
PSIS is a common finding in patients with pituitary hor-
mone deficiency and accounts for hypopituitarism
in.11%of adult patients (8) and in 29 of 46 childrenwith
idiopathic growth hormone deficiency (9). Although me-
chanical pituitary stalk rupture or pituitary stalk ischemia
during breechdelivery has been implicated as amajor cause
of PSIS, the existence of familial cases has suggested that a
genetic disorder involving developmental processes un-
derlies at least some cases of PSIS, and mutations and/or
single nucleotide variants in HESX1 (MIM 601802),
LHX4 (MIM 602146), PROP1 (MIM 601538), OTX2
(MIM 600037), SOX3 (MIM 313430), PROKR2 (MIM
607123), and GPR161 (MIM 612250) have been identi-
fied in patients with this condition (2, 3, 10). Our un-
derstanding of the genetic basis of this disease continues to
grow; complex inheritance patterns and interpreting the
significance of variation are two important challenges (2).
Despite the increasing availability of high-throughput ge-
netic sequencing techniques,most patientswith PSIS do not
have an identified genetic cause. Here, we have used an
unbiased approach, WES, to identify a genetic basis for
PSIS. The proband we studied carried heterozygous mis-
sense mutations in two different genes important for
hypothalamic/pituitary function, PROKR2 and WDR11.
This finding implicates a putative digenic basis for PSIS in
this child and also suggests that this unusual genetic
mechanism may explain other cases of PSIS that lack
conventional autosomal-recessive inheritance.
A digenic disorder results from heterozygous muta-
tions in two distinct genes that encode different proteins.
Often, these proteins are both required for normal
function or development of a tissue, and/or act in the
same signaling pathway. The effect of having mutations
in two different genes in the same pathway can be more
than additive; together they can produce a more severe
phenotype than would be expected to occur from the
simple combination of their individual effects. For a long
time, the existence of digenic inheritance has been pro-
posed as one potential explanation for why in some
pedigrees, a monogenic model of inheritance suggests
decreased or variable penetrance (11). In these families,
a two-locus model may more accurately reflect the
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observed patterns. Examples of digenic inheritance include
some forms of retinitis pigmentosa and facioscapulo-
humeral muscular dystrophy and, perhaps more rele-
vantly, in some forms of idiopathic hypogonadotropic
hypogonadism (12). The number of conditions exhibiting
digenic inheritance continues to grow (13). Indeed, a
curated database exists [DIDA (DIgenic Diseases Data-
base)] and at the time of this writing contains 44 con-
ditions with clear evidence of digenic inheritance (14).
Although we report on heterozygous mutations in
both PROKR2 and WDR11 in the same individual,
each of these genes has previously been implicated
with another gene mutation as the basis for a digenic
pituitary disease. PROKR2 encodes
a 384-amino acid G-protein–coupled
receptor (GPCR) whose signaling ac-
tivity plays a key role in both devel-
opment of the olfactory bulb (15) and
gonadotropin-releasing hormone se-
cretion (16). Mutations in PROKR2
have previously been associated with
hypogonadotropic hypogonadism with
or without anosmia and Kallmann
syndrome (17).
Several lines of evidence indicate
that PROKR2 p.R85C is pathogenic.
First, the amino acid change (from
basic to hydrophobic) occurs at a
highly evolutionarily conserved site
that is predicted to lie within an im-
portant functional G-protein–coupled
receptor domain, and in silico studies
predict that this change is pathological (PolyPhen-2 score
of 1.0 predicts the change is probably damaging; PRO-
VEAN score of26.840 is deleterious). Second, functional
studies have indicated that the p.R85C variant has re-
duced activity in mitogen-activated protein kinase and/or
calcium signaling pathways (17–19) without evidence
of a dominant negative effect (19). Third, this mutation
has previously been identified in an individual with
normosomic idiopathic hypogonadotropic hypogonad-
ism (17). The same heterozygous mutation on PROKR2
that was identified in the proband here, c.253C.T;p.
R85C, has also been found in a female patient with
combined pituitary hormone deficiencies, including inGH,
Figure 3. Mutant WDR11 fails to accumulate in the nucleus after treatment with leptomycin B. (a) HEK293 cells transfected with GFP-WDR11
(green) expression constructs were treated with leptomycin B (Lep), an inhibitor of nuclear export, or the vehicle (solv) and analyzed by
fluorescence microscopy to determine the intracellular localization of WDR11. Nuclei were stained with DAPI (blue). (b) The percentages of cells
showing nuclear or cytoplasmic localization of the mutant WDR11-GFP are shown in comparison with the WT, which showed a significant
increase of nuclear translocation after Lep treatment. The average data from three independent experiments were obtained by counting 100 to
200 cells in each experiment and are presented as mean 6 standard error of the mean with two-way analysis of variance followed by Tukey post
hoc test. NS, P . 0.05; ****P , 0.0001.
Figure 2. Mutant WDR11 fails to bind to EMX1. (a) WDR11 fusion proteins containing
a Myc epitope tag WT or the c.1306A.G variant (mutant) were coexpressed in HEK293 cells
along with HA-EMX1 protein. The total cell lysates were immunoprecipitated with anti-Myc
antibody, and the association of EMX1 protein was determined by immunoblot analysis using
anti-EMX1 antibody. Empty pcDNA vector (-) was included as a negative control. (b) The
average densitometry values of the EMX1 band intensity obtained from three independent
experiments are shown with the standard deviations (error bars).
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adrenocorticotropic hormone, luteinizing hormone, and
follicle-stimulating hormone, as well as vasopressin, and
magnetic resonance imaging demonstrating normal anterior
pituitary, absent posterior pituitary, and absent stalk (20).
No additional mutations were found in that patient; how-
ever, only two candidate genes [PROKR2 and FGFR1
(MIM 136350)] were sequenced for individuals in that
study. Finally, all other amino acid changes reported at the
same site have been also associated with hypothalamic and
pituitary dysfunction. For example, heterozygousmutations,
including PROKR2 c.254G.A;p.R85H (rs74315418),
c.253C.G;p.R85G (rs141090506), and c.254G.T;p.
R85L (rs74315418), have all been identified in association
with pituitary stalk interruption and combined pituitary
hormone deficiencies (21, 22). On the basis of the American
College of Medical Genetics and Genomics guidelines (23),
this variant is therefore classified as pathogenic.
In addition, in themousemodel of PROKR2deficiency,
the Kallmann syndrome phenotype is observed only in the
homozygous animals (18). In human studies as well as in
animal models, PROKR2 haploinsufficiency seems not to
account for the PSIS phenotype, hence raising the need
for a “second hit,” either genetic or environmental, to
produce pituitary disease. This hypothesis was further
supported when a patient with Kallmann syndrome was
discovered to carry the same PROKR2 heterozygous
mutation as our proband, p.R85C, in combination with a
second heterozygous mutation in FGFR1, c.1810G.A;p.
A604T (NM_023110.2), thereby providing evidence for a
digenic basis for the syndrome (22). Prokineticin 2 and
PROKR2 are both expressed in the hypothalamus and
pituitary, and reduced expression or activity of PROKR2
is implicated in both Kallmann syndrome and PSIS, per-
haps because of the important role this signaling pathway
plays in endocrine angiogenesis and neuronal migration in
this region of the central nervous system. Ectopic posterior
pituitary has been proposed to be a consequence of de-
fective neuronal axon projections along the pituitary stalk
or defective angiogenesis of hypophyseal portal circula-
tion. Therefore, it is reasonable to suggest that the loss of
PROKR2 signaling is involved in PSIS.
Our proband carried a second heterozygous mutation
inWDR11, which encodes a protein that is a member of
the WD repeat protein family that participates in a wide
variety of cellular processes. The p.I436V missense mu-
tation affects the sixth WD domain of the WRD11
protein within the evolutionarily conserved predicted
propeller region that is required for interaction of WDR11
with EMX1, a homeodomain transcription factor neces-
sary for olfactory bulb morphogenesis. We found that the
p.I436V mutation, similar to other nearby amino acid
substitutions that have been identified in individuals with
idiopathic hypogonadotropic hypogonadism with and
without anosmia (7, 24), disrupted interaction of WDR11
with EMX1. Specifically, heterozygousmissensemutations
in neighboring residues A435 (c.1303G.A;p.A435T;
rs318240760) and R448 (c.1343G.A;p.R448Q;
rs144440500) have been identified in each of two in-
dividuals with idiopathic hypogonadotropic hypogonadism
and normosmia (7). In addition, in a different individual, the
WDR11 p.A435T mutation was identified in association
with a mutation in a second gene, GNRHR (c.275T.C;p.
L92P; MIM 138850; NM_000406.2), implicating digenic
inheritance of this disorder as well (24). This variant has
been identified in homozygous form in two people (http://
exac.broadinstitute.org/gene/ENSG00000120008), but
their phenotype is unknown, and it is conceivable that
one or both of these individuals has a mild pituitary
phenotype.
Digenic inheritance is more likely when the functional
roles of the two involved proteins affect a singular pathway
and/or there are demonstrated protein-protein interactions
(13).Here, bothPROKR2 andWDR11participated in key
signaling processes that influence the morphogenesis of the
olfactory bulb, although they are not in the same singular
pathway, nor do they have an established protein–protein
interaction. The PROKR2 p.R85C variant has been de-
scribed in a heterozygous state in patients with idiopathic
hypogonadotropic hypogonadism, Kallmann syndrome,
healthy first-degree relatives of Kallmann probands, and
rare healthy controls. We therefore propose that p.R85C
(and possibly other PROKR2 mutations) may act as a
modifier and contribute to the PSIS phenotype through
digenic inheritance, as previously demonstrated in idio-
pathic hypogonadotropic hypogonadism and Kallmann
syndrome (12, 25). Further studies are needed to elucidate
in more detail the role of PROKR2 signaling in pituitary
and midline development.
In summary, this case adds digenic inheritance of
mutations in PROKR2 andWDR11 as a potential cause
of combined pituitary hormonal deficiencies and PSIS,
and it highlights the importance of considering un-
conventional genetic mechanisms when there is in-
complete segregation of a heterozygous mutation with
the phenotype in a pedigree.
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